

# Analysis of risk factors for lateral lymph node metastasis in T1 stage papillary thyroid carcinoma: a retrospective cohort study

Yuanyuan Fan<sup>#</sup>, Xun Zheng<sup>#</sup>, Yanhao Ran, Pengyu Li, Tianfeng Xu, Yujie Zhang, Tao Wei<sup>^</sup>

Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China

*Contributions:* (I) Conception and design: Y Fan, X Zheng; (II) Administrative support: T Wei; (III) Provision of study materials or patients: T Wei; (IV) Collection and assembly of data: Y Fan, X Zheng, Y Ran, P Li, T Xu, Y Zhang; (V) Data analysis and interpretation: Y Fan, X Zheng, T Wei; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work as co-first authors.

*Correspondence to:* Tao Wei, PhD. Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu 610041, China. Email: surgeonwei5776@163.com.

**Background:** The occurrence of cervical lymph node metastasis in T1 stage papillary thyroid carcinoma (PTC) is frequently observed. Notably, lateral lymph node metastasis (LLNM) emerges as a critical risk factor adversely affecting prognostic outcomes in PTC. The primary aim of this investigation was to delineate the risk factors associated with LLNM in the initial stages of PTC.

**Methods:** This retrospective analysis encompassed 3,332 patients diagnosed with T1 stage PTC without evident LLNM at the time of diagnosis. These individuals underwent primary surgical intervention at West China Hospital, Sichuan University between June 2017 and February 2023. The cohort was divided into two groups: patients manifesting LLNM and those without metastasis at the time of surgery. Additionally, T1 stage PTC patients were subdivided into T1a and T1b categories. Factors influencing LLNM were scrutinized through both univariate and multivariate analyses.

**Results:** The incidence of LLNM was observed in 6.2% of the cohort (206 out of 3,332 patients). Univariate analysis revealed significant correlations between LLNM and male gender ( $P<0.001$ ), tumor localization in the upper lobe ( $P<0.001$ ), maximal volume of the primary tumor ( $P<0.001$ ), largest tumor diameter ( $P<0.001$ ), multifocality ( $P<0.001$ ), and bilaterality ( $P<0.001$ ), with the exception of age ( $P=0.788$ ) and duration of active surveillance (AS) ( $P=0.978$ ). Multivariate logistic regression analysis identified male gender ( $P<0.001$ ), upper lobe tumor location ( $P<0.001$ ), maximal primary tumor volume ( $P<0.001$ ), and multifocality ( $P<0.001$ ) as independent predictors of LLNM. However, age categories ( $\leq 55$ ,  $>55$  years), maximum tumor diameter, bilaterality, and surveillance duration did not exhibit a significant impact. Comparative analyses between T1a and T1b subgroups showed congruent univariate results but revealed differences in multivariate outcomes. In the T1a subgroup, gender, tumor location, and multifocality (all  $P<0.05$ ) were associated with elevated LLNM risk. Conversely, in the T1b subgroup, tumor location, dimensions, and multifocality (all  $P<0.05$ ) were significant predictors of LLNM risk, whereas gender ( $P=0.097$ ) exerted a marginal influence.

**Conclusions:** The investigation highlights several key risk factors for LLNM in T1 stage PTC patients, including gender, upper lobe tumor location, larger tumor size, and multifocality. Conversely, prolonged AS and younger age did not significantly elevate LLNM risk, suggesting the viability of AS as a strategic option in selected cases.

**Keywords:** Papillary thyroid carcinoma (PTC); lateral lymph nodes; metastasis; risk factors

Submitted Nov 16, 2023. Accepted for publication Feb 10, 2024.

doi: 10.21037/gs-23-470

View this article at: <https://dx.doi.org/10.21037/gs-23-470>

<sup>^</sup> ORCID: 0000-0001-5413-9129.

## Introduction

### Background

Papillary thyroid carcinoma (PTC) constitutes the most prevalent histological variant among thyroid malignancies, accounting for approximately 89.1% of all cases. This statistic, however, shows a marginal decline between 2014 and 2018 (1). Patients diagnosed with PTC typically demonstrate favorable prognostic outcomes and low mortality rates. Nonetheless, early-stage metastasis to the cervical lymph nodes is not uncommon. Prior research (2-5) indicates that lymph node metastases are present in about 20% to 90% of PTC cases. Although central lymph node metastasis does not markedly alter the prognosis for PTC patients (6), the emergence of lateral lymph node metastasis (LLNM, N1b) often necessitates more complex and prolonged surgical procedures, potentially impacting patient prognosis adversely (7,8).

A study by Sapuppo *et al.* (7) categorized PTC patients

based on their postoperative pathologic N status. Findings indicated that individuals classified at the N1b stage showed an increased incidence of structural diseases, including locoregional lymph node and/or distant metastases, compared to those in the N0 and N1a stages. At their final follow-up, N1b stage patients exhibited a higher likelihood of persistent or recurrent disease relative to those in the N1a category. Moreover, those with lateral LN metastasis demonstrated reduced disease-free and 10-year disease-related survival rates (9,10). A notable study observed a 3.0% mortality rate among N1b patients, significantly higher than that in N1a and N0 patients (11), suggesting that LLN positivity is a strong prognostic indicator for poor outcomes in PTC.

The American Thyroid Association (ATA) management guidelines for differentiated thyroid cancer (DTC) recommend central and/or lateral lymph node dissection when metastasis is clinically or radiographically evident, while cautioning against routine prophylactic dissection of lateral lymph nodes (12). The efficacy of prophylactic level VI (central) neck dissection in cN0 disease remains a topic of debate (12). Confirmed LLNMs necessitate additional lateral lymph node dissection, extending the surgery's complexity and duration. Such procedures also increase the likelihood of postoperative complications, including celiac leakage, hemorrhage, nerve injury, shoulder discomfort, and restricted mobility (13). Consequently, the development of prognostic methods for LLNM is essential in managing node metastasis and recurrence in PTC.

Despite extensive research into LLNM risk factors in PTC, findings have been inconsistent (8,14-20). Our study explored major risk factors such as patient age, gender, primary tumor location, tumor diameter, multifocality, and bilaterality. Additionally, we hypothesized that primary tumor volume and duration of active surveillance (AS) post-diagnosis could also contribute to LLNM risk. These variables were thus comprehensively integrated into our analysis.

AS involves monitoring cancer patients without immediate surgical or radiation intervention unless the disease progresses. In 1993, Dr. Akira Miyauchi proposed delayed surgical intervention as an alternative to immediate surgery for papillary thyroid microcarcinoma (PTMC, tumor diameter <1 cm) at a symposium hosted at Kuma Hospital, Japan. Subsequent trials in 2003 and 2010 corroborated the feasibility of this approach (21,22), and numerous patients in Korea have been studied (23), showcasing AS as a promising alternative for PTMC treatment. Ho *et al.*'s comprehensive study (24) found

### Highlight box

#### Key findings


- In this retrospective study of 3,332 patients with T1 stage papillary thyroid carcinoma (PTC), we found factors (male gender, upper lobe tumor, larger volume, and multifocality) linked to lateral lymph node metastasis (LLNM) risk. Patients without these risks, particularly in T1b stage PTC, may benefit from short-term active surveillance (AS), underscoring the importance of an assertive approach in cases with increased tumor size.

#### What is known and what is new?

- In early-stage PTC, there is a propensity for cervical lymph node metastasis, with lateral compartment involvement correlating with an adverse prognosis for patients.
- In our study, tumor volume, not diameter, strongly correlated with LLNM risk. Notably, younger patients showed no significant increase in this risk. In T1a stage PTC, males had a closer association with LLNM, while in T1b stage PTC, tumor size played a more crucial role.

#### What is the implication, and what should change now?

- In clinical practice, patients with identified risk factors necessitate routine follow-up and careful consideration of the optimal timing for surgical intervention due to heightened vulnerability to lateral nodal metastasis. Nevertheless, those lacking these risks, especially younger patients, may consider short-term AS, justifying its adoption when these risk factors are absent. In T1a stage PTC, male gender prompts careful evaluation for immediate surgical intervention. In T1b stage PTC, increased tumor size emphasizes the necessity for a more assertive treatment approach.



**Figure 1** Flow chart of the selection of study population. PTC, papillary thyroid carcinoma; LLNM, lateral lymph node metastasis.

no significant mortality risk difference between 1.0- and 2.0-cm thyroid tumors. However, a tumor diameter of >2 cm independently correlates with an increased risk of cancer-related death. Therefore, for all T1 stage (<2 cm) tumors, AS may be a feasible alternative to immediate surgery (24,25). AS also appears as a potential therapeutic option for recurrent lymph node metastasis in DTC (26,27). During AS, most low-risk PTC patients did not develop new lymph node metastases (28-30). However, the direct link between AS and the occurrence of LLN metastasis has not been comprehensively documented.

### Objective

This retrospective cohort study aims to identify risk factors for LLNM development, providing insights for the timing of surgical interventions in clinical practice and contributing

to informed clinical decision-making and patient welfare. We present this article in accordance with the STROBE reporting checklist (available at <https://gs.amegroups.com/article/view/10.21037/gS-23-470/rc>).

## Methods

### Patients

This study entailed a retrospective cohort analysis of 3,332 patients diagnosed with PTC, who underwent initial thyroidectomy at West China Hospital, Sichuan University, from June 2017 to February 2023. A detailed methodology flowchart is provided in *Figure 1*. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study protocol was approved by the Ethics Committee of West China Hospital of Sichuan University

(2023 No. 2098). Individual consent for this retrospective analysis was waived. All participants underwent their first thyroid surgery and were confirmed to have no other histopathological types of thyroid carcinoma. The cohort was bifurcated based on the presence or absence of LLNM, as ascertained by postoperative pathological evaluation. Further, these patients were segregated into T1a (<10 mm) and T1b (>10 mm) categories, contingent on the maximum diameter of the tumor.

The inclusion criteria encompassed: definitive postoperative histological diagnosis of PTC; absence of suspicious LLNM on ultrasonography at the initial PTC diagnosis; and comprehensive medical records. The exclusion criteria included: intraoperative or postoperative histopathological identification of non-PTC pathology; previous thyroid surgical procedures; presence of LLNM on ultrasonography or distant metastasis on computed tomography/magnetic resonance imaging (CT/MRI) at the initial PTC diagnosis; and incomplete medical records.

#### Data collection

Clinical and pathological data were collated from electronic medical records and pathology reports.

Patient demographic information (gender and age), and the time of initial fine-needle aspiration biopsy (FNAB) confirming PTC can be retrieved from the electronic medical records. The ultrasonography report provided tumor characteristics (maximum diameter, volume, location) and clinical details (multifocality, bilaterality, and LLNM status). The tumor volume (in mm<sup>3</sup>) was computed employing the ellipsoid volume equation:  $\pi/6 \times \text{length} \times \text{width} \times \text{height}$ . The features of suspect malignant lymph node involvement include (with at least one of the following features): (I) microcalcifications; (II) partially cystic appearance; (III) increased peripheral or diffuse vascularity; (IV) hyperechoic tissue looking like thyroid. The characteristic of indeterminate lymph node: disappearance of lymphatic hilum and at least one of the following characteristics: round shape; increased short axis,  $\geq 8$  mm in level II and  $\geq 5$  mm in levels III and IV; absence of central vascularization (12,31,32). We conducted lymph node assessment according to those criteria. For a few indeterminate lymph nodes, after discussing with the patient, we opted for either lymph node fine-needle aspiration with thyroglobulin washout fluid testing or immediate surgery. For the LLNM group, the period of AS before surgery was demarcated as the interval from

the initial FNAB confirming PTC, to the first detection of LLNM via preoperative ultrasound, subsequently corroborated by postoperative pathology. For the non-LLNM cohort, this duration was defined as the time span between the initial FNAB diagnosis of PTC and the admission for surgery. Quantitative data, including age, primary tumor's maximum diameter and volume, and waiting time for surgery, were transformed into qualitative categories based on predetermined cut-off values.

#### Statistical analysis

Continuous variables were converted into categorical data for analysis using SPSS version 25. The Chi-squared test was employed to compare demographic and tumor characteristics, including gender, age, tumor size, tumor location, and AS duration between the LLNM and non-LLNM groups. Multifactorial analysis was performed using binary logistic regression. A P value of less than 0.05 (two-tailed) was considered indicative of statistical significance.

## Results

#### Patient characteristics and group analysis

Among 3,332 PTC patients meeting inclusion and exclusion criteria, 206 presented with LLNM. The clinical and pathological characteristics of all participants are delineated in *Table 1*. The average AS time of the LLNM group is  $137.9 \pm 145.7$  days. The LLNM group had a significantly higher proportion of males at 37.4% (77/206) compared to the non-LLNM group at 23.5% ( $P < 0.001$ ). The mean age in the metastasis cohort was  $41.6 \pm 10.9$  years, which did not significantly differ from that of the non-metastasis group ( $P = 0.729$ ). Tumor location was categorized as upper lobe or non-upper lobe (inclusive of middle and lower lobes and the isthmus). A higher proportion of upper lobe tumors was observed in the LLNM group (38.8%) compared to the non-LLNM group (25.0%) ( $P < 0.001$ ). Additionally, significant differences were noted in the maximum tumor diameter ( $11.5 \pm 4.1$  mm in the LLNM group versus  $9.0 \pm 3.5$  mm in the non-LLNM group,  $P < 0.001$ ) and maximum tumor volume ( $603.1 \pm 569.4$  mm<sup>3</sup> in the LLNM group versus  $318.6 \pm 377.2$  mm<sup>3</sup> in the non-LLNM group,  $P < 0.001$ ). Higher incidences of multifocal and bilateral tumors were observed in the LLNM group (29.1% and 18.0%, respectively) compared to the non-LLNM group ( $P < 0.05$  for both).

**Table 1** Clinical and pathological characteristics for LLNM risk of T1 stage PTC patients by univariate analysis (n=3,332)

Category	Non-LLNM (n=3,126)	LLNM (n=206)	Total	OR (95% CI)	P value
Sex				1.945 (1.450–2.610)	<0.001
Female	2,392 (76.5)	129 (62.6)	2,521 (75.7)		
Male	734 (23.5)	77 (37.4)	811 (24.3)		
Age (years)				0.939 (0.595–1.482)	0.788
≤55	2,773 (88.7)	184 (89.3)	2,957 (88.7)		
>55	353 (11.3)	22 (10.7)	375 (11.3)		
Mean ± SD	41.3±10.8	41.6±10.9			0.729
Tumor location				0.525 (0.393–0.703)	<0.001
Upper lobe	782 (25.0)	80 (38.8)	862 (25.9)		
Non-upper lobe	2,344 (75.0)	126 (61.2)	2,470 (74.1)		
Tumor volume (mm <sup>3</sup> )					<0.001
<319	2,149 (68.7)	78 (37.9)	2,227 (66.8)	1.000	
319–603	504 (16.1)	50 (24.3)	554 (16.6)	2.733 (1.892–3.949)	<0.001
>603	473 (15.1)	78 (37.9)	551 (16.5)	4.543 (3.269–6.315)	<0.001
Mean ± SD	318.6±377.2	603.1±569.4			<0.001
Tumor diameter (mm)				2.917 (2.167–3.927)	<0.001
≤12	2,595 (83.0)	129 (62.6)	2,724 (81.8)		
>12	531 (17.0)	77 (37.4)	608 (18.2)		
Mean ± SD	9.0±3.5	11.5±4.1			<0.001
Multifocality				2.444 (1.780–3.354)	<0.001
No	2,676 (85.6)	146 (70.9)	2,822 (84.7)		
Yes	450 (14.4)	60 (29.1)	510 (15.3)		
Bilaterality				1.907 (1.312–2.771)	0.001
No	2,804 (89.7)	169 (82.0)	2,973 (89.2)		
Yes	322 (10.3)	37 (18.0)	359 (10.8)		
AS time (months)				0.983 (0.719–1.381)	0.978
≤6	2,350 (75.2)	155 (75.2)	2,505 (75.2)		
>6	776 (24.8)	51 (24.8)	827 (24.8)		

Data are reported as n (%), unless noted otherwise. P values represent the statistically difference between the groups with and without LLNMs, unless noted otherwise. LLNM, lateral lymph node metastasis; PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval; SD, standard deviation; AS, active surveillance.

### Univariate and multivariate analyses

Univariate analysis (*Table 1*) revealed that male gender, primary tumor location in the upper lobe, larger tumor volume, greater tumor diameter, multifocal, and bilateral tumors were all significantly associated with LLNM (all

$P < 0.001$ ). The multivariate analysis was presented in *Table 2*. Male patients exhibited approximately double the risk of LLNM compared to females [odds ratio (OR) = 1.782,  $P < 0.001$ ]. The presence of primary tumors in the upper lobes (OR = 1.975,  $P < 0.001$ ), larger tumor volumes (319–603 mm<sup>3</sup>, OR = 2.546,  $P < 0.001$ ; >603 mm<sup>3</sup>, OR = 4.784,



**Table 2** Multivariate analysis of the risk factors for LLNM of T1 stage PTC patients (n=3,332)

Variables	OR (95% CI)	P value
Sex		
Female	Reference	
Male	1.782 (1.315–2.417)	<0.001
Age (years)		
≤55	1.207 (0.755–1.931)	0.432
>55	Reference	
Tumor location		
Upper lobe	1.975 (1.461–2.670)	<0.001
Non-upper lobe	Reference	
Tumor volume (mm <sup>3</sup> )		<0.001
<319	Reference	
319–603	2.546 (1.731–3.744)	<0.001
>603	4.784 (2.676–8.553)	<0.001
Tumor diameter (mm)		0.359
≤12	Reference	
>12	0.900 (0.525–1.546)	0.704
Multifocality	3.254 (1.976–5.358)	<0.001
Bilaterality	0.606 (0.337–1.089)	0.094
AS time (months)		
≤6	Reference	
>6	1.080 (0.771–1.514)	0.654

LLNM, lateral lymph node metastasis; PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval; AS, active surveillance.

P<0.001), and multifocality (OR =3.254, P<0.001) were also significantly correlated with an increased risk of LLNM. Gender-specific analyses (Table 3) did not reveal a significant correlation between AS duration and LLNM risk.

### Subgroup analysis: T1a and T1b groups

Supplementary material present clinical and pathological data for T1a and T1b subgroups, respectively. Univariate analysis (Tables S1,S2) indicated common LLNM risk factors: male gender, upper lobe tumor location, larger tumor size, and multifocality. Multifactorial regression analysis (Table 4) highlighted that gender was a significant risk factor

for LLNM in the T1a group (P<0.001) but not in the T1b group (P=0.097). Furthermore, no significant differences were observed in age and AS duration between LLNM and non-LLNM groups in both subgroups (Tables S3,S4).

## Discussion

In this extensive retrospective analysis of 3,332 patients, we observed a positive association between factors such as male gender, upper lobe tumor location, larger tumor volume, and multifocality with the risk of LLNM. This finding underscores the necessity of routine follow-up and careful consideration of the optimal timing for surgical intervention, particularly when these factors coexist. Conversely, factors like age, tumor diameter, bilateral tumor presence, and extended AS duration did not demonstrate a substantial correlation with lateral nodal involvement.

Aligning with Mao *et al.*'s meta-analysis (14), our study reaffirms male sex as a risk factor for LLNM in T1 stage PTC patients, highlighting a higher propensity for LLNM in men. This gender-based disparity in LLNM incidence aligns with several studies (15,33), although it remains a subject of debate in other research (34,35). Notably, the adverse prognosis associated with PTC tends to be more pronounced in men, despite its higher prevalence in women (36). This suggests the need for rigorous evaluation of immediate thyroid surgery in male patients, particularly in T1a stage PTC.

Though the traditional belief that younger age (<55 years) is a risk factor for lymph node metastasis (17,34), our study found no significant age-related differences in LLNM risk, potentially supporting the potential role of AS in specific cases.

Primary tumor location significantly affects lymph node dissemination, as supported by our findings in agreement with prior research (19,37–39). Given the complex drainage patterns and higher postoperative complication risks associated with upper thyroid tumors, accurate LLNM assessment in clinical practice is paramount.

While PTMC is generally considered low-risk for LLNM (12), our study suggests that larger tumor diameters do not necessarily predict LLNM, diverging from some previous research (40). By incorporating tumor volume in our analysis, we found a strong association between greater tumor volumes and an increased risk of LLNM. This finding is supported by research emphasizing tumor volume as a more reliable prognostic marker than diameter (41). These results highlight the importance of careful surgical

**Table 3** Univariate analysis of active surveillance time of T1 stage PTC patients

Gender	AS time (months)	Non-LLNM	LLNM	Total	OR (95% CI)	P value
Female (n=2,521)	≤6	1,789	95	1,884	1.062 (0.710–1.588)	0.770
	>6	603	34	637		
Male (n=811)	≤6	561	60	621	0.919 (0.522–1.616)	0.769
	>6	173	17	190		
Female (n=2,521)	≤12	2,131	119	2,250	0.686 (0.355–1.325)	0.259
	>12	261	10	271		
Male (n=811)	≤12	647	71	718	0.628 (0.265–1.489)	0.287
	>12	87	6	93		
Female (n=2,521)	≤24	2,325	129	2,454	–	0.100
	>24	67	0	67		
Male (n=811)	≤24	719	74	793	1.943 (0.550–6.868)	0.520
	>24	15	3	18		

PTC, papillary thyroid carcinoma; AS, active surveillance; LLNM, lateral lymph node metastasis; OR, odds ratio; CI, confidence interval.

**Table 4** Multivariate analysis of the risk factors for LLNM of T1a (n=2,318) and T1b (n=1,014) PTC patients

Variables	T1a (n=2,318)		T1b (n=1,014)	
	OR (95% CI)	P value	OR (95% CI)	P value
Sex				
Female	Reference		Reference	
Male	2.253 (1.444–3.515)	<0.001	1.426 (0.937–2.169)	0.097
Age (years)				
≤55	0.712 (0.392–1.295)	0.266	2.075 (0.968–4.448)	0.061
>55	Reference		Reference	
Tumor location				
Upper lobe	2.131 (1.367–3.323)	0.001	1.951 (1.286–2.960)	0.002
Non-upper lobe	Reference		Reference	
Tumor volume (mm <sup>3</sup> )				
≤140	Reference		Reference	
>140	1.960 (0.884–4.346)	0.098	2.072 (1.222–3.516)	0.007
Tumor diameter (mm)				
≤7	Reference		Reference	
>7	0.955 (0.432–2.111)	0.909	1.268 (0.745–2.158)	0.382
Multifocality	2.780 (1.273–6.072)	0.01	3.461 (1.747–6.857)	<0.001
Bilaterality	0.791 (0.321–1.950)	0.611	0.596 (0.268–1.326)	0.205
AS time (months)				
≤6	Reference		Reference	
>6	1.314 (0.821–2.103)	0.256	0.944 (0.578–1.541)	0.817

LLNM, lateral lymph node metastasis; PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval; AS, active surveillance.

planning for patients with larger tumor volumes.

Our analysis identified multifocality as a LLNM risk factor, contrary to some studies that suggest both multifocality and bilaterality increase LLNM risk (39). Multifocality's prognostic significance, especially in tumors larger than 1 cm, is well-established (42). However, our findings do not support the hypothesis that bilaterality, an indicator of tumor invasiveness, heightens LLNM risk.

Our study delves into the potential impact of AS duration on LLNM risk. With the emerging role of AS in managing T1a and potentially T1b stage PTC (25,43), there is increasing focus on understanding the association between surveillance duration and LLNM risk. Within *Table 3*, we performed separate analyses employing surveillance duration thresholds of 6, 12, and 24 months (*Table 3*, all P values >0.05). The selection of these thresholds values was informed by clinical practice. These analyses reveal that, for those with stage T1 PTC, there were no notable differences in the distribution of time to AS between the LLNM and non-LLNM groups. In the subgroups of T1a and T1b, we encountered equivalent results. Hence, our findings suggest that short-term AS ( $\leq 24$  months) may not considerably increase the risk of LLNM in T1 stage PTC patients, which is in accordance with the conclusions of previous studies (44,45). Further research, particularly focusing on long-term surveillance, is warranted to substantiate these findings.

LLNM is associated with a poor prognosis in patients (46). Nevertheless, the current indication for performing cervical lateral lymph node dissection in PTC cases remain subject to debate. According to the ATA management guidelines, patients are recommended for LLN dissection when clinical or radiographic evidence supports the presence of lymph node disease (12). Ultrasonography is the primary tool for diagnosing cN1b, but its sensitivity was found to be only 0.70 (95% CI: 0.68–0.72;  $I^2=96.7\%$ ) (47). Building on our earlier discussion, preoperative patients presenting with male gender, upper lobe tumor location, larger tumor dimension, and multifocality are indicative of a heightened risk of LLNM. These high-risk factors discourage AS and instead favor lateral lymph node dissection surgery. The identification of high-risk factors for predicting LLN metastasis contributes to decisions regarding total thyroidectomy and lateral lymph node dissection in PTC patients, as well as guides surgeons in evaluating and treating cervical lateral lymph nodes during postoperative follow-up. Postoperative adjuvant therapy for PTC typically

comprises TSH suppression therapy and radioactive iodine treatment (48). For high-risk thyroid cancer patients, TSH levels are generally maintained below 0.1 mU/L (12). Moreover, patients with suspected or confirmed lymph node metastasis and extrathyroidal tumor extension might necessitate an increased radioactive iodine dosage to further diminish the risk of recurrence (49). Consequently, for postoperative patients meeting all the aforementioned risk factors, it seems justifiable to adopt a proactive approach in deciding on TSH suppression therapy and radioactive iodine treatment to minimize the risk of PTC recurrence after surgery.

This study, being retrospective and single-center, has its limitations, including the lack of uniformity in tumor location assessment and the absence of a separate analysis for different types of lymph node metastasis. Future multicenter, prospective studies with larger sample sizes and extended follow-up periods are necessary to address these gaps and further explore the nuances of LLNM in PTC.

## Conclusions

In summary, this retrospective analysis has identified several critical risk factors for LLNM in patients with T1 stage PTC. These include male gender, tumor location in the upper third of the thyroid gland, a maximum tumor volume exceeding 603 mm<sup>3</sup>, and the presence of multifocal tumors. In clinical practice, patients exhibiting this constellation of risk factors should give serious thought to surgical intervention due to their increased vulnerability to lateral nodal metastasis.

On the other hand, for patients not displaying these risk factors, the consideration of a short-term AS strategy may be appropriate. Our findings indicate that extended periods of AS, especially in younger patients, do not significantly escalate the risk of LLNM. This observation offers a viable justification for adopting AS in certain patient cohorts, particularly when the risk factors mentioned above are absent.

It is also noteworthy that in patients with T1a stage PTC, male gender should trigger a careful evaluation of the need for immediate surgical intervention. However, in the context of T1b stage PTC, the influence of gender appears less pronounced. Rather, an increase in tumor size emerges as a pivotal factor in elevating the risk of LLNM, underscoring the necessity for a more assertive treatment approach in these cases.



## Acknowledgments

*Funding:* This work was supported by the Sichuan University West China Hospital Discipline Excellence Development 1·3·5 Project (No. ZYJC21033).

## Footnote

*Reporting Checklist:* The authors have completed the STROBE reporting checklist. Available at <https://gs.amegroups.com/article/view/10.21037/gS-23-470/rc>

*Data Sharing Statement:* Available at <https://gs.amegroups.com/article/view/10.21037/gS-23-470/dss>

*Peer Review File:* Available at <https://gs.amegroups.com/article/view/10.21037/gS-23-470/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://gs.amegroups.com/article/view/10.21037/gS-23-470/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study protocol was approved by the Ethics Committee of West China Hospital of Sichuan University (2023 No. 2098). Individual consent for this retrospective analysis was waived.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Megwalu UC, Moon PK. Thyroid Cancer Incidence and Mortality Trends in the United States: 2000-2018. *Thyroid* 2022;32:560-70.
2. Wang Y, Zheng J, Hu X, et al. A retrospective study of papillary thyroid carcinoma: Hashimoto's thyroiditis as a protective biomarker for lymph node metastasis. *Eur J Surg Oncol* 2023;49:560-7.
3. Luo Y, Zhao Y, Chen K, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. *J Endocrinol Invest* 2019;42:227-36.
4. Feng JW, Yang XH, Wu BQ, et al. Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma. *Clin Transl Oncol* 2019;21:1482-91.
5. Wang Y, Deng C, Shu X, et al. Risk Factors and a Prediction Model of Lateral Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma Patients With 1-2 Central Lymph Node Metastases. *Front Endocrinol (Lausanne)* 2021;12:716728.
6. Viola D, Materazzi G, Valerio L, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. *J Clin Endocrinol Metab* 2015;100:1316-24.
7. Sapuppo G, Palermo F, Russo M, et al. Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome. *J Endocrinol Invest* 2017;40:1355-63.
8. Huang Y, Yin Y, Zhou W. Risk Factors for Central and Lateral Lymph Node Metastases in Patients With Papillary Thyroid Micro-Carcinoma: Retrospective Analysis on 484 Cases. *Front Endocrinol (Lausanne)* 2021;12:640565.
9. Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. *Endocr J* 2009;56:177-92.
10. Moreno MA, Agarwal G, de Luna R, et al. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. *Arch Otolaryngol Head Neck Surg* 2011;137:157-62.
11. Sapuppo G, Tavarelli M, Russo M, et al. Lymph node location is a risk factor for papillary thyroid cancer-related death. *J Endocrinol Invest* 2018;41:1349-53.
12. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26:1-133.
13. Heng Y, Yang Z, Zhou L, et al. Risk stratification for lateral involvement in papillary thyroid carcinoma

- patients with central lymph node metastasis. *Endocrine* 2020;68:320-8.
14. Mao J, Zhang Q, Zhang H, et al. Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)* 2020;11:265.
  15. Zhu J, Huang R, Yu P, et al. Male Gender Is Associated with Lymph Node Metastasis but Not with Recurrence in Papillary Thyroid Carcinoma. *Int J Endocrinol* 2022;2022:3534783.
  16. Kruijff S, Petersen JF, Chen P, et al. Patterns of structural recurrence in papillary thyroid cancer. *World J Surg* 2014;38:653-9.
  17. Zhao H, Huang T, Li H. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer. *Surgery* 2019;166:55-60.
  18. Feng JW, Wu WX, Qi GF, et al. Nomograms based on sonographic and clinicopathological characteristics to predict lateral lymph node metastasis in classic papillary thyroid carcinoma. *J Endocrinol Invest* 2022;45:2043-57.
  19. Heng Y, Feng S, Yang Z, et al. Features of Lymph Node Metastasis and Structural Recurrence in Papillary Thyroid Carcinoma Located in the Upper Portion of the Thyroid: A Retrospective Cohort Study. *Front Endocrinol (Lausanne)* 2021;12:793997.
  20. Feng JW, Qin AC, Ye J, et al. Predictive Factors for Lateral Lymph Node Metastasis and Skip Metastasis in Papillary Thyroid Carcinoma. *Endocr Pathol* 2020;31:67-76.
  21. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* 2003;13:381-7.
  22. Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. *World J Surg* 2010;34:28-35.
  23. Kwon H, Oh HS, Kim M, et al. Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea. *J Clin Endocrinol Metab* 2017;102:1917-25.
  24. Ho AS, Luu M, Zalt C, et al. Mortality Risk of Nonoperative Papillary Thyroid Carcinoma: A Corollary for Active Surveillance. *Thyroid* 2019;29:1409-17.
  25. Ho AS, Kim S, Zalt C, et al. Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial. *JAMA Oncol* 2022. [Epub ahead of print]. doi: 10.1001/jamaoncol.2022.3875.
  26. Walter LB, Scheffel RS, Zanella AB, et al. Active Surveillance of Differentiated Thyroid Cancer Metastatic Cervical Lymph Nodes: A Retrospective Single-Center Cohort Study. *Thyroid* 2023;33:312-20.
  27. Jerkovich F, Abelleira E, Bueno F, et al. Active Surveillance of Small Metastatic Lymph Nodes as an Alternative to Surgery in Selected Patients with Low-Risk Papillary Thyroid Cancer: A Retrospective Cohort Study. *Thyroid* 2022;32:1178-83.
  28. Ze Y, Zhang X, Shao F, et al. Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence. *J Cancer Res Clin Oncol* 2019;145:2751-9.
  29. Sugitani I. Active surveillance of low-risk papillary thyroid microcarcinoma. *Best Pract Res Clin Endocrinol Metab* 2023;37:101630.
  30. Smulever A, Pitoia F. Conservative management of low-risk papillary thyroid carcinoma: a review of the active surveillance experience. *Thyroid Res* 2023;16:6.
  31. Ha EJ, Chung SR, Na DG, et al. 2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations. *Korean J Radiol* 2021;22:2094-123.
  32. Health Commission Of The People's Republic Of China N. National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version). *Chin J Cancer Res* 2022;34:131-50.
  33. Ding J, Wu W, Fang J, et al. Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma. *Sci Rep* 2020;10:4141.
  34. Liu Q, Pang WT, Dong YB, et al. Analysis of risk factors for lateral lymph node metastasis in papillary thyroid carcinoma: A retrospective cohort study. *World J Otorhinolaryngol Head Neck Surg* 2022;8:274-8.
  35. Masui T, Adachi S, Uemura H, et al. Risk factors for the lateral cervical lymph node metastasis of papillary thyroid carcinoma: A clinical study. *Mol Clin Oncol* 2023;18:25.
  36. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. *Future Oncol* 2010;6:1771-9.
  37. Hunt JP, Buchmann LO, Wang L, et al. An analysis of factors predicting lateral cervical nodal metastases in papillary carcinoma of the thyroid. *Arch Otolaryngol Head Neck Surg* 2011;137:1141-5.
  38. Xiang D, Xie L, Xu Y, et al. Papillary thyroid microcarcinomas located at the middle part of the middle third of the thyroid gland correlates with the presence of neck metastasis. *Surgery* 2015;157:526-33.
  39. So YK, Kim MJ, Kim S, et al. Lateral lymph node

- metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis for prevalence, risk factors, and location. *Int J Surg* 2018;50:94-103.
40. Hu D, Zhou J, He W, et al. Risk factors of lateral lymph node metastasis in cN0 papillary thyroid carcinoma. *World J Surg Oncol* 2018;16:30.
  41. Lim ST, Jeon YW, Suh YJ. The Prognostic Values of Preoperative Tumor Volume and Tumor Diameter in T1N0 Papillary Thyroid Cancer. *Cancer Res Treat* 2017;49:890-7.
  42. Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. *Ann Surg Oncol* 2015;22:125-31.
  43. Sakai T, Sugitani I, Ebina A, et al. Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. *Thyroid* 2019;29:59-63.
  44. Miyauchi A, Ito Y, Fujishima M, et al. Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience. *Thyroid* 2023;33:817-25.
  45. Ito Y, Miyauchi A. Active Surveillance May Be the Best Initial Management for Papillary Thyroid Microcarcinoma. *J Endocr Soc* 2023;7:bvad063.
  46. Bayadsi H, Nylén C, Sandström M, et al. Risk factors for recurrent disease in small papillary thyroid cancers - a Swedish register-based study. *Langenbecks Arch Surg* 2023;408:162.
  47. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: Diagnosis of central and lateral compartment nodal metastases. *Eur J Radiol* 2019;112:14-21.
  48. Houten PV, Netea-Maier RT, Smit JW. Differentiated thyroid carcinoma: An update. *Best Pract Res Clin Endocrinol Metab* 2023;37:101687.
  49. Chu KP, Baker S, Zenke J, et al. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence. *Thyroid* 2018;28:902-12.

**Cite this article as:** Fan Y, Zheng X, Ran Y, Li P, Xu T, Zhang Y, Wei T. Analysis of risk factors for lateral lymph node metastasis in T1 stage papillary thyroid carcinoma: a retrospective cohort study. *Gland Surg* 2024. doi: 10.21037/gs-23-470

**Table S1** Clinical and pathological characteristics for LLNM risk of T1a PTC patients by univariate analysis (n=2,318)

Category	Non-LLNM (n=2,228)	LLNM (n=90)	Total	OR (95% CI)	P value
Sex				2.287 (1.479–3.535)	<0.001
Female	1,743 (78.2)	55 (61.1)	1,798 (77.6)		
Male	485 (21.8)	35 (38.9)	520 (22.4)		
Age (years)				1.512 (0.842–2.715)	0.164
≤55	1,986 (89.1)	76 (84.4)	2,062 (89.0)		
>55	242 (10.9)	14 (15.6)	256 (11.0)		
Mean ± SD	41.5±10.5	42.7±11.3			0.386
Tumor location				0.513 (0.332–0.792)	0.002
Upper lobe	548 (24.6)	35 (38.9)	583 (25.2)		
Non-upper lobe	1,680 (75.4)	55 (61.1)	1,735 (74.8)		
Tumor volume (mm <sup>3</sup> )				1.944 (1.270–2.975)	0.002
≤140	1,332 (59.8)	39 (43.3)	1,371 (59.1)		
>140	896 (40.2)	51 (56.7)	947 (40.9)		
Mean ± SD	140.4±99.0	181.4±114.8			<0.001
Tumor diameter (mm)				1.725 (1.129–2.633)	0.011
≤7	1,316 (59.1)	41 (45.6)	1,357 (58.5)		
>7	912 (40.9)	49 (54.4)	961 (41.5)		
Mean ± SD	7.1±1.7	7.7±1.6			0.003
Multifocality				2.407 (1.494–3.877)	<0.001
No	1,921 (86.2)	65 (72.2)	1,986 (85.7)		
Yes	307 (13.8)	25 (27.8)	332 (14.3)		
Bilaterality				2.014 (1.152–3.520)	0.012
No	2,012 (90.3)	74 (82.2)	2,086 (90.0)		
Yes	216 (9.7)	16 (17.8)	232 (10.0)		
AS time (months)				1.244 (0.785–1.972)	0.353
≤6	1,657 (74.4)	63 (70.0)	1,720 (74.2)		
>6	571 (25.6)	27 (30.0)	598 (25.8)		

Data are reported as n (%), unless noted otherwise. P values represent the statistically difference between the groups with and without LLNM, unless noted otherwise. LLNM, lateral lymph node metastasis; PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval; AS, active surveillances.

**Table S2** Clinical and pathological characteristics for LLNM risk of T1b PTC patients by univariate analysis (n=1,014)

Category	Non-LLNM (n=898)	LLNM (n=116)	Total	OR (95% CI)	P value
Sex				1.479 (0.986–2.220)	0.057
Female	649 (72.3)	74 (63.8)	723 (71.3)		
Male	249 (27.7)	42 (36.2)	291 (28.7)		
Age (years)				0.525 (0.249–1.106)	0.085
≤55	787 (87.6)	108 (93.1)	895 (88.3)		
>55	111 (12.4)	8 (6.9)	119 (11.7)		
Mean ± SD	40.8±11.5	40.8±10.5			0.963
Tumor location				0.556 (0.372–0.831)	0.004
Upper lobe	234 (26.1)	45 (38.8)	279 (27.5)		
Non-upper lobe	664 (73.9)	71 (61.2)	735 (72.5)		
Tumor volume (mm <sup>3</sup> )				2.191 (1.483–3.238)	<0.001
≤760	575 (64.0)	52 (44.8)	627 (61.8)		
>760	323 (36.0)	64 (55.2)	387 (38.2)		
Mean ± SD	760.4±443.9	930.2±566.3			<0.001
Tumor diameter (mm)				1.817 (1.229–2.685)	0.002
≤14	607 (67.6)	62 (53.4)	669 (66.0)		
>14	291 (32.4)	54 (46.6)	345 (34.0)		
Mean ± SD	13.7±2.4	14.5±2.7			<0.001
Multifocality				2.281 (1.477–3.524)	<0.001
No	755 (84.1)	81 (69.8)	836 (82.4)		
Yes	143 (15.9)	35 (30.2)	178 (17.6)		
Bilaterality				1.652 (0.988–2.762)	0.054
No	792 (88.2)	95 (81.9)	887 (87.5)		
Yes	106 (11.8)	21 (18.1)	127 (12.5)		
AS time (months)				0.882 (0.548–1.419)	0.604
≤6	693 (77.2)	92 (79.3)	785 (77.4)		
>6	205 (22.8)	24 (20.7)	229 (22.6)		

Data are reported as n (%), unless noted otherwise. P values represent the statistically difference between the groups with and without LLNMs, unless noted otherwise. LLNM, lateral lymph node metastasis; PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval; AS, active surveillance.

**Table S3** Univariate analysis of AS time of T1a PTC patients (n=2,318)

Gender	AS time (months)	Non-LLNM	LLNM	Total	OR (95% CI)	P value
Female (n=1,798)	≤6	1,292	37	1,329	1.394 (0.786–2.473)	0.254
	>6	451	18	469		
Male (n=520)	≤6	365	26	391	1.053 (0.480–2.310)	0.898
	>6	120	9	129		
Female (n=1,798)	≤12	1,557	48	1,605	1.221 (0.544–2.737)	0.628
	>12	186	7	193		
Male (n=520)	≤12	428	33	461	0.455 (0.106–1.947)	0.417
	>12	57	2	59		
Female (n=1,798)	≤24	1,694	55	1,749	0.969 (0.960–0.977)	0.401
	>24	49	0	49		
Male (n=520)	≤24	476	34	510	1.556 (0.191–12.641)	>0.99
	>24	9	1	10		

AS, active surveillance; PTC, papillary thyroid carcinoma; LLNM, lateral lymph node metastasis; OR, odds ratio; CI, confidence interval.

**Table S4** Univariate analysis of AS time of T1b PTC patients (n=1,014)

Gender	AS time (months)	Non-LLNM	LLNM	Total	OR (95% CI)	P value
Female (n=723)	≤6	497	58	555	0.902 (0.504–1.615)	0.728
	>6	152	16	168		
Male (n=291)	≤6	196	34	230	0.870 (0.380–1.991)	0.742
	>6	53	8	61		
Female (n=723)	≤12	574	71	645	0.323 (0.099–1.052)	0.049
	>12	75	3	78		
Male (n=291)	≤12	219	38	257	0.768 (0.256–2.305)	0.638
	>12	30	4	34		
Female (n=723)	≤24	631	74	705	–	0.290
	>24	18	0	18		
Male (n=291)	≤24	243	40	283	2.025 (0.395–10.386)	0.725
	>24	6	2	8		

AS, active surveillance; PTC, papillary thyroid carcinoma; LLNM, lateral lymph node metastasis; OR, odds ratio; CI, confidence interval.